For the medical-diagnostic routine, this means that in systemically ill patients who are to receive anti-FGFR2 therapy, FGFR2 biomarker testing should be extended to the biologically driving tumor component, which can also only become apparent in metastases. Here, FGFR2 is linked to neoplasm.